TW202304455A - 用於治療子宮漿液性癌之ｗｅｅ１化合物 - Google Patents

用於治療子宮漿液性癌之ｗｅｅ１化合物 Download PDF

Info

Publication number
TW202304455A
TW202304455A TW111113723A TW111113723A TW202304455A TW 202304455 A TW202304455 A TW 202304455A TW 111113723 A TW111113723 A TW 111113723A TW 111113723 A TW111113723 A TW 111113723A TW 202304455 A TW202304455 A TW 202304455A
Authority
TW
Taiwan
Prior art keywords
administered
use according
therapeutically effective
day
effective amount
Prior art date
Application number
TW111113723A
Other languages
English (en)
Chinese (zh)
Inventor
飛利浦 普特
迪米崔歐斯 沃利歐提斯
馬可斯 羅德里奎茲 維安那
費南多 杜奈特
鍾 彼特勞斯 魯德夫 德
亞玫德 亞迪 沙曼塔
凱文 杜安 班納
琴華 黃
Original Assignee
美商瑞卡瑞恩Ｉｐ控股有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商瑞卡瑞恩Ｉｐ控股有限責任公司 filed Critical 美商瑞卡瑞恩Ｉｐ控股有限責任公司
Publication of TW202304455A publication Critical patent/TW202304455A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
TW111113723A 2021-04-12 2022-04-11 用於治療子宮漿液性癌之ｗｅｅ１化合物 TW202304455A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163174005P 2021-04-12 2021-04-12
US202163174004P 2021-04-12 2021-04-12
US63/174,004 2021-04-12
US63/174,005 2021-04-12

Publications (1)

Publication Number Publication Date
TW202304455A true TW202304455A (zh) 2023-02-01

Family

ID=83640600

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111113723A TW202304455A (zh) 2021-04-12 2022-04-11 用於治療子宮漿液性癌之ｗｅｅ１化合物

Country Status (7)

Country Link
US (1) US20240197743A1 (https=)
EP (1) EP4322958A4 (https=)
JP (1) JP2024517085A (https=)
AU (1) AU2022259496A1 (https=)
CA (1) CA3213804A1 (https=)
TW (1) TW202304455A (https=)
WO (1) WO2022221143A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020384291A1 (en) 2019-11-15 2022-05-26 Recurium Ip Holdings, Llc Chiral synthesis of a tertiary alcohol
BR112023000350A2 (pt) 2020-07-09 2023-03-28 Recurium Ip Holdings Llc Sais e formas de um inibidor de wee1
EP4615459A4 (en) * 2022-11-08 2026-04-29 Zeno Man Inc Intermittent dosing regimen for azenosertib in treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020009372A (es) * 2018-03-09 2020-10-14 Recurium Ip Holdings Llc 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas.
US12318452B2 (en) 2018-09-27 2025-06-03 Dana-Farber Cancer Institute, Inc. Degraders of WEE1 kinase
WO2020210320A1 (en) * 2019-04-11 2020-10-15 Recurium Ip Holdings, Llc Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones

Also Published As

Publication number Publication date
AU2022259496A1 (en) 2023-10-12
EP4322958A4 (en) 2025-04-09
WO2022221143A1 (en) 2022-10-20
US20240197743A1 (en) 2024-06-20
CA3213804A1 (en) 2022-10-20
EP4322958A1 (en) 2024-02-21
JP2024517085A (ja) 2024-04-19

Similar Documents

Publication Publication Date Title
TW202304455A (zh) 用於治療子宮漿液性癌之ｗｅｅ１化合物
US20240197739A1 (en) Combination Comprising Ribociclib and Amcenestrant
EP4110326B1 (en) Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
US20240335447A1 (en) Wee1 inhibitor for cancer
CN104918619B (zh) 稳定的肠胃外dnj组合物
US20250208149A1 (en) Wee1 compound for treating uterine serous carcinoma
EP4342475A1 (en) Composition for treatment of covid-19 comprising taurodeoxycholic acid or pharmaceutically acceptable salt thereof as active ingredient
CN118139625A (zh) Wee1抑制剂和抗cd47抗体的组合
JP7640033B2 (ja) ピリド［１，２－ａ］ピリミジノン類似体の使用
EP4587026A1 (en) Combinations
US20230038138A1 (en) Combination therapy for treating cancer
US20030012825A1 (en) Metallized molecule therapies
CN115701990A (zh) 用于治疗冠状病毒感染、反转录病毒感染和丙型肝炎的药品/药物
Kent et al. An anticopper antiangiogenic approach for advanced cancer in spontaneously occurring tumors using tetrathiomolybdate: a pilot study in a canine animal model
US20250161276A1 (en) Drug combinations and methods of treating ovarian cancer
RU2516027C2 (ru) Комбинация противораковых агентов
US20240390373A1 (en) Raf kinase inhibitors for treating tumors harboring gene fusions
CN117500505A (zh) 用于治疗子宫浆液性癌的wee1化合物
TW202308641A (zh) 用於治療癌症之方法及包含cdk抑制劑之給藥方案
CN100455289C (zh) 孟德拉明类抗癌药
Mallayasamy Dr Physiologically based pharmacokinetic modelling of Aminophylline and Caffeine
EP3804719A1 (en) Use of 2,3,5-substituted thiophene compound for enhancement of radiotherapy
TW202608448A (zh) 藥物組合及其應用
JP2023519662A (ja) ミエロペルオキシダーゼ阻害剤を用いて筋萎縮性側索硬化症を処置する方法
JP2020536846A (ja) Ｆｇｆｒ選択的チロシンキナーゼ阻害剤を含む医薬組成物